证券代码：002004 证券简称：华邦健康 公告编号：2024023 华邦生命健康股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于 2023 年 12 月 27 日召开 第八届董事会第十六次会议，全体董事出席并全票审议通过了《关于回购公司股 份方案的议案》。同意公司使用自有资金以集中竞价交易方式回购公司股份，回 购资金总额不低于人民币 2,000 万元（含），不超过人民币 3,000 万元（含）；回 购价格为不超过人民币 7.21 元/股；回购期限为公司自董事会审议通过本回购方 案之日起 12 个月内。具体内容详见公司在《证券时报》、《中国证券报》、《上海 证券报》及巨潮资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案 的公告》（公告编号：2023037）、《回购股份报告书》（公告编号：2023040）。 因公司实施 2023 年度权益分派，向全体股东每 10 股派 2.20 元人民币现金， 根据公司《回购股份报告书》的约定,本次回购股份价格上限由不 ...

证券代码：002004 证券简称：华邦健康 公告编号：2024022 华邦生命健康股份有限公司 2023年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、根据《中华人民共和国公司法》、《深圳证券交易所上市公司自律监管指 引第 9 号——回购股份》等相关规定，华邦生命健康股份有限公司（以下简称"公 司"）通过回购专用账户持有的公司股份 3,505,808 股不参与此次权益分派。 2、截至本公告披露日，以公司现有总股本 1,979,919,191 股扣除公司回购专 户上已回购股份 3,505,808 股后的股本总额 1,976,413,383 股为基数计算，预计派 发现金股利 434,810,944.26 元（含税）。 3、本次权益分派按公司总股本折算的每 10 股现金红利为 2.196104 元（即 分红总额/总股本*10=434,810,944.26 元/1,979,919,191 股*10，保留六位小数，最 后一位直接截取，不四舍五入），即每股现金红利为 0.2196104 元/股。在保证本 次权益分派方案不变的前提下，本 ...

经过三十多年的耕耘公司目前形成了以大健康产业为主要发展方向多元化运营平台协同发展的经营模式业务范围涵盖医药、医疗、农化、新材料、旅游等五大领域 就公司结构而言华邦健康本身是一家上市公司我们旗下还控股三家上市公司此凯盛新财、尹泰生物、丽江股份以及控股一家新三板挂牌企业秦宁旅游就财务情况而言我们2023年 截至年底净资产是166亿元总资产有300亿元营业收入116亿元较去年同期下滑12%规模净利润为3亿较去年同期下滑30%左右但是剔除商域的影响2023年我们的规模净利润是5.08亿元2022年规模净利润为9.03亿元 虽然业绩2023年有所下滑 但是我们华邦健康的主业十分稳定医药业绩一直都在稳步的发展 医疗业务也是非常迅速旅游版化因为是2023年疫情放开后的第一年 迎来大幅增长 丽江旅游业绩也创历史新高 业绩下滑的主要原因是农化新材料板块受2022年是化工大年2023年是化工小年的影响所以两家化工行业的公司尤其是引钛生物的业绩出现比较大幅度的影响可能不是那么熟悉华邦的朋友会有疑问为什么公司会涉及这么多板块所以我简要介绍一下我们的发展历程 华邦的整体发展历程可以分为三个阶段1992年到2004年我们生根医药以皮肤药 ...

欢迎各位线上的投资者参加华安医药联合录影中举办的夏季线上策略会本场是上市公司华巴安健康的一个交流我们也是很荣幸的邀请到了公司的总理彭总和我们进行一个分享今天的交流主要分为两个环节首先有请彭总对公司目前的一个新情况最新的一个进展做一个介绍接下来我们把时间交给彭总好的 各位朋友以及线上的投资者们大家下午好 感谢华安医药联合鹿眼中举办的这次夏季线上策略会让我们能够有机会与各位在此交流也感谢各位对华邦的关注首先稍微纠正一下我是华邦健康的艾二扬新月然后由我为各位简要介绍一下华邦健康的最新情况当然出席本次交流的还有我们的董事会秘书彭云辉女士我们都在同一个接口那接下来我就通过这么一个PPT为各位简单介绍一下华邦的最新情况 我会从四个部分介绍一下公司情况公司概况以及我们的大健康产业独立资本运营平台以及我们的投资价值 华邦健康成立于1992年是国内皮肤临床用药以及皮肤健康领域的领先企业2004年我们在深交所挂牌上市也是首批中小板上市的8家企业之一经过30多年的耕耘公司目前形成了以大健康产业为主要发展方向多元化运营平台协同发展的经营模式业务范围涵盖医药医疗农化新材料旅游等五大领域 就公司结构而言,华邦健康本身是一家上市公司,我们 ...

证券代码：002004 证券简称：华邦健康 公告编号：2024020 二、其他说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托 1 一、回购公司股份的进展情况 截至2024年4月30日，公司通过集中交易方式累计回购公司股份3,505,808 股，占公司目前总股本的 0.18%。最高成交价为 4.65 元/股，最低成交价为 3.88 元/股，支付的总金额为 15,585,611.15 元（不含交易费用），本次回购符合公司 的回购股份方案及相关法律法规的要求。 华邦生命健康股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于 2023 年 12 月 27 日召开 第八届董事会第十六次会议，全体董事出席并全票审议通过了《关于回购公司股 份方案的议案》。同意公司使用自有资金以集中竞价交易方式回购公司股份，回 购资金总额不低于人民币 2,000 万元（含），不超过人民币 3,000 万元（含）；回 购价格为不超过人民币 7.21 元/股；回购期限为公司自董事会审议 ...

华邦生命健康股份有限公司 2023 年度独立董事述职报告 （刘忠海） 各位股东及股东代表： 作为华邦生命健康股份有限公司（以下简称"公司"）的独立董事，本人在 2023 年度严格按照《公司法》、《上市公司独立董事管理办法》、《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》、《公司章程》、《独 立董事工作制度》等有关规定，本着对全体股东负责的态度，忠实地履行独立董 事的职责，谨慎、认真、勤勉地行使了独立董事的权力。积极出席公司董事会、 股东大会，对公司重大事项发表客观、审慎、公正的独立意见，积极维护公司整 体利益和全体股东特别是中小股东的合法权益，对公司规范、稳定、健康地发展 起到了积极的推动作用。现就本人 2023 年度任职期间的履职情况汇报如下： 一、个人基本情况 （一）工作履历 刘忠海先生，中国籍，1975 年生，西南政法大学法学学士、清华五道口金 融 EMBA，现任本公司独立董事，金科地产集团股份有限公司监事会主席。同 时担任重庆顺博铝合金股份有限公司、国城矿业股份有限公司独立董事。曾任新 华社记者、中国证券报社记者，深圳证券信息公司西南办事处主任，上市公司金 科股份董事会秘书 ...

封生命健康股份有限公司2023年度非经营性资金占用及其他关联资金往来情况汇总表 单位:人民币万元 | 非经营性资金占用 | | 占用方与上市公司 | 上市公司核算 | 2023年期初占用 | 2023年度占用累计 | 2023年度占用资 | 2023年度偿还累 | 2023年期末占 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 14 | 资金占用方名称 --- | 的关联关系 | 的会计科目 | 资金余额 | 发生金额(不含利息) 金的利息(如有) | | 计发生金额 | 用资金余额 | 占用形成原因 | | | 控股股东、实际控制~ | 111 | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 其他 ...

证券代码：002004 证券简称：华邦健康 公告编号：2024011 华邦生命健康股份有限公司 第八届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开及议案审议情况 华邦生命健康股份有限公司（以下简称"公司"）第八届董事会第十八次会 议通知于 2024 年 4 月 15 日以电子邮件的形式发出，2024 年 4 月 25 日通过现场 +视频会议的方式召开，公司 6 名董事都参加了本次会议，会议的通知及召开符 合《公司法》及《公司章程》的规定，合法有效。会议由董事长张松山先生主持， 经与会各位董事认真讨论研究，审议通过了以下议案： 本议案尚需提交至公司 2023 年年度股东大会审议。 （三）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023 1 年度财务决算报告》； （一）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023 年度总经理工作报告》； （二）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023 年度董事会工作报告》； 详见公司于同日在巨潮资讯网（w ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥11.59 billion, a decrease of 12.38% compared to ¥13.23 billion in 2022[36]. - The net profit attributable to shareholders for 2023 was approximately ¥302.12 million, down 30.30% from ¥433.28 million in 2022[36]. - The net profit after deducting non-recurring gains and losses for 2023 was approximately ¥243.07 million, a decline of 40.55% from ¥408.65 million in 2022[36]. - The net cash flow from operating activities for 2023 was approximately ¥1.59 billion, a decrease of 33.99% compared to ¥2.41 billion in 2022[36]. - The total assets at the end of 2023 were approximately ¥30.73 billion, an increase of 2.32% from ¥30.02 billion at the end of 2022[37]. - The net assets attributable to shareholders at the end of 2023 were approximately ¥10.10 billion, a decrease of 0.85% from ¥10.19 billion at the end of 2022[37]. - The basic earnings per share for 2023 were ¥0.1526, down 30.29% from ¥0.2188 in 2022[36]. - The weighted average return on net assets for 2023 was 2.99%, a decrease of 1.26% from 4.25% in 2022[36]. - The company reported a net profit of ¥177.14 million in Q1 2023, with a significant drop to -¥202.80 million in Q4 2023[41]. - The company achieved a total operating revenue of 1,159,459.04 million yuan, a decrease of 163,777.52 million yuan, representing a year-on-year decline of 12.38%[56]. - The operating profit was 92,651.12 million yuan, down by 71,848.85 million yuan, reflecting a year-on-year decrease of 43.68%[56]. - The net profit attributable to shareholders was 30,212.20 million yuan, a reduction of 13,136.15 million yuan, which is a year-on-year decline of 30.30%[56]. Revenue Growth in Medical Business - In 2023, the company achieved significant revenue growth in its medical business, with Beijing Huasheng Rehabilitation Hospital's income increasing substantially after obtaining Beijing's medical insurance qualification, and bed utilization rates continuing to rise[2]. - Chongqing Songshan Hospital's medical revenue grew by over 40% in 2023, with bed utilization rates at a healthy level, driven by optimized discipline layout and talent introduction[8]. - Beijing Huasheng Rehabilitation Hospital reported a rapid increase in operating income and a bed utilization rate exceeding 80% in 2023, with 300 beds open across 16 departments[9]. - The company will continue to innovate its medical service business model, focusing on the "big health" industry[7]. - The company is implementing a three-step development strategy for its hospitals, focusing on building high-quality medical teams and enhancing service quality[135]. - The company plans to develop a modern health service system at Chongqing Songshan Hospital while improving service quality and brand image[135]. Product Development and Innovation - The company launched 14 new functional skincare products, including three types of azelaic acid acne creams, further enriching its "big skin" product matrix[4]. - The company has expanded its product offerings, including the approval of Moxifloxacin Sodium Chloride Injection, enhancing its portfolio in dermatology, tuberculosis, and oncology, contributing to new revenue growth points[60]. - The company has launched several new products in the dermatology segment, including the Tri-Retinoic Acid Acne Gel and Tri-Retinoic Acid Clear Gel, leveraging its 30 years of clinical experience in dermatology[60]. - The company is focusing on expanding its OTC market presence and enhancing its overseas raw material drug market efforts[54]. - The company is focusing on developing high-value-added raw materials and key intermediates through collaboration with domestic and international research institutions[132]. - The company intends to expand its product range to include functional skincare products, transitioning from disease treatment to disease prevention and daily care[132]. Research and Development - The company emphasizes the importance of internal collaboration and has established Huabong Pharmaceutical Research Institute to enhance its R&D capabilities[2]. - The company has a strong R&D team focused on technological innovation, which supports product quality and profitability[71]. - Research and development expenses increased by 8.80% year-on-year, totaling ¥419,138,741.86 in 2023[108]. - The number of R&D personnel rose by 5.31% to 1,349, with a notable increase in master's degree holders by 34.06%[112]. - The company has developed 2 first-class new drugs and over 20 generic drugs, with more than 180 patents granted, showcasing strong R&D capabilities[84]. - The company is focusing on improving product competitiveness through innovative process verification stages[110]. Market Expansion and Strategic Partnerships - The company has established long-term partnerships with international pharmaceutical companies such as Abbott, Johnson & Johnson, Eli Lilly, and Merck, focusing on the export of active pharmaceutical ingredients to developed countries like Europe, America, and Japan[58]. - The company has covered over 200,000 retail endpoints, actively expanding its marketing channels in response to national healthcare reforms, including partnerships with over 10 online platforms such as Alibaba Health and Meituan[61]. - The company is actively developing high-end and specialty raw materials at its Changshou and Hanchong International raw material production bases, which have recently commenced operations[60]. - The company is enhancing its digital transformation across production bases, aiming for high efficiency, quality, and eco-friendliness in its operations[60]. - The company is focusing on expanding its OTC market presence and enhancing its overseas raw material drug market efforts[54]. - The company aims to expand sales and market presence by enhancing global market network and increasing customer base[139]. Tourism Business Performance - The company’s tourism segment saw a significant recovery, with Lijiang Co. achieving record-high operating revenue due to increased visitor numbers[55]. - The domestic tourism market in 2023 experienced a rapid recovery after three years of decline, with inbound and outbound tourism markets achieving expected growth[146]. - The company aims to enhance its tourism business by developing a scenic transportation system and mid-to-high-end accommodation, leveraging resources from its platforms, Huabang Yikang and Lijiang Co.[147]. - The tourism performance is supported by famous 5A scenic spots in provinces like Yunnan and Guangxi, enhancing visitor experiences[72]. - Increased competition in the tourism market, particularly from international hotel brands, is a concern; the company plans to improve hotel quality and control operating costs to enhance revenue[148]. Governance and Compliance - The company maintains a governance structure that complies with regulations, ensuring transparency and protecting the rights of all shareholders, especially minority investors[152]. - The board of directors consists of six members, including two independent directors, ensuring compliance with legal requirements and promoting effective decision-making[153]. - The company has established specialized committees within the board to provide scientific and professional opinions, enhancing the decision-making process[153]. - The company has a complete and independent business system, capable of independently formulating product marketing strategies without reliance on shareholders[161]. - The company has established a robust internal control environment with clear responsibilities and checks and balances[191]. - The internal control audit report indicated that the company maintained effective financial reporting internal controls as of December 31, 2023[196]. Environmental and Safety Measures - The company has increased its investment in environmental protection and safety measures, ensuring a stable operational environment[68]. - The company has complied with all relevant environmental protection laws and regulations during its operations[199]. - The company obtained an environmental management system certification in accordance with GB/T24001-2016/ISO14001:2015 standards[200]. - The company has implemented strict controls on wastewater, waste gas, solid waste, and noise emissions to meet regulatory standards[199]. - The company is focusing on green production technologies to reduce waste generation and improve economic efficiency[76]. - Safety production risks are present due to the handling of hazardous chemicals, necessitating strict adherence to safety regulations[140]. Challenges and Risks - The company faces risks related to raw material price fluctuations, which significantly impact business costs and gross margins[144]. - Environmental protection risks arise from increasing regulatory scrutiny, potentially leading to higher operational costs[140]. - The company has established a risk-sharing mechanism with clients to mitigate foreign exchange risks associated with international sales[141]. - The company has implemented measures to mitigate risks from natural disasters and pandemics, including research and preventive strategies to enhance resilience[148]. - The company has undergone changes in its main business operations, expanding into healthcare services and new materials since 2015[35]. Shareholder Engagement and Remuneration - The company distributed a cash dividend of RMB 2.20 per 10 shares, totaling RMB 434,810,944.26, which represents 100% of the profit distribution amount[186]. - The total distributable profit for the period was RMB 1,053,716,228.03, indicating a strong profitability[188]. - The total remuneration for directors, supervisors, and senior management in 2023 amounted to 8.7475 million yuan, linked to their positions and performance[173]. - The annual shareholders meeting had an investor participation rate of 26.97% on May 17, 2023, and the first extraordinary shareholders meeting had a participation rate of 28.52% on December 20, 2023[162]. - The company has not implemented any stock incentive plans or employee stock ownership plans during the reporting period[190].

| 四川华信(集团)会计师事务所 | 地址:成都市洗面桥街 18 号金茂礼都南 28 楼 | | --- | --- | | | 电话:(028) 85560449 | | (特殊普通合伙) | 传真:(028) 85560449 | | | 邮编:610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) | 电邮: schxzhb@hxcpa.com.cn | 华邦生命健康股份有限公司 2023 年度审计报告 川华信审(2024)第 0030 号 目录: 1、审计报告 2、合并及母公司资产负债表 3、合并及母公司利润表 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn 4、合并及母公司现金流量表 5、合并及母公司所有者权益变动表 6、财务报表附注 华邦牛命健康股份有限公司 审计报告 审计报告 川华信审(2024)第 0030 号 华邦生命健康股份有限公司全体股东: 一、审计意见 我们审计了华邦生命健康股份有限公司(以下简称"华邦生命健康"或"贵公司"财务 报表,包括 2023年12月 31日的合并及母公司资产负债表,202 ...